scholarly journals Micro‐elimination of Hepatitis C in Low‐ and Middle‐Income Settings: Challenges and Windows of Opportunity

2021 ◽  
Author(s):  
Enrique Wolpert Barraza ◽  
David Kershenobich Stalnikowitz ◽  
Jorge Enrique Guerrero Guerrero ◽  
Alethse Torre Rosas
Keyword(s):  
Hepatitis C ◽  
Middle Income ◽  
Windows Of Opportunity ◽  
Low And Middle Income

LBP-37-Evaluation of Hepatitis C Virus Rapid Diagnostic Test in HCV mono- and HCV/HIV co-infected patients from Low and Middle Income Countries

2019 ◽  
Vol 70 (1) ◽  
pp. e159-e160
Author(s):  
Beatrice Vetter ◽  
Elena Ivanova Reipold ◽  
Rosemary Audu ◽  
Maia Alkhazashvili ◽  
Anja De Weggheleire ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Diagnostic Test ◽  
Rapid Diagnostic Test ◽  
Middle Income ◽  
Middle Income Countries ◽  
Low And Middle Income

scholarly journals Potential market size and impact of hepatitis C treatment in low‐ and middle‐income countries

2016 ◽  
Vol 23 (7) ◽  
pp. 522-534 ◽  
Author(s):  
M. E. Woode ◽  
M. Abu‐Zaineh ◽  
J. Perriëns ◽  
F. Renaud ◽  
S. Wiktor ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Market Size ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Middle Income Countries ◽  
Potential Market ◽  
Low And Middle Income

scholarly journals Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study

10.2196/16863 ◽  
2020 ◽  
Vol 9 (7) ◽  
pp. e16863
Author(s):  
Bridget Louise Draper ◽  
Alisa Pedrana ◽  
Jessica Howell ◽  
Win Lei Yee ◽  
Hla Htay ◽  
...  
Keyword(s):  
Hepatitis C ◽  
General Population ◽  
Feasibility Study ◽  
People Who Inject Drugs ◽  
Point Of Care ◽  
Community Based ◽  
Middle Income ◽  
Hepatitis C Rna ◽  
Direct Acting ◽  
Low And Middle Income

Background The advent of direct-acting antivirals (DAAs) and point-of-care (POC) testing platforms for hepatitis C allow for the decentralization of care to primary care settings. In many countries, access to DAAs is generally limited to tertiary hospitals, with limited published research documenting decentralized models of care in low-and middle-income settings. Objective This study aims to assess the feasibility, acceptability, effectiveness, and cost-effectiveness of decentralized community-based POC testing and DAA therapy for hepatitis C among people who inject drugs and the general population in Yangon, Myanmar. Methods Rapid diagnostic tests for anti-hepatitis C antibodies were carried out on-site and, if reactive, were followed by POC GeneXpert hepatitis C RNA polymerase chain reaction tests. External laboratory blood tests to exclude other major health issues were undertaken. Results were given to participants at their next appointment, with the participants commencing DAA therapy that day if a specialist review was not required. Standard clinical data were collected, and the participants completed behavioral questionnaires. The primary outcome measures are the proportion of participants receiving GeneXpert hepatitis C RNA test, the proportion of participants commencing DAA therapy, the proportion of participants completing DAA therapy, and the proportion of participants achieving sustained virological response 12 weeks after completing DAA therapy. Results Recruitment was completed on September 30, 2019. Monitoring visits and treatment outcome visits are scheduled to continue until June 2020. Conclusions This feasibility study in Myanmar contributes to the evidence gap for community-based hepatitis C care in low- and middle-income settings. Evidence from this study will inform the scale-up of hepatitis C treatment programs in Myanmar and globally.

Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia

2015 ◽  
Vol 26 (11) ◽  
pp. 1081-1087 ◽  
Author(s):  
Niklas Luhmann ◽  
Julie Champagnat ◽  
Sergey Golovin ◽  
Ludmila Maistat ◽  
Edo Agustian ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Eastern Europe ◽  
People Who Inject Drugs ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Low And Middle Income

scholarly journals Barriers to access to hepatitis C treatment

2016 ◽  
Vol 10 (04) ◽  
pp. 308-316 ◽  
Author(s):  
Hava Yilmaz ◽  
Esmeray Mutlu Yilmaz ◽  
Hakan Leblebicioglu
Keyword(s):  
Hepatitis C ◽  
Diagnostic Testing ◽  
Antiviral Agents ◽  
Drug Market ◽  
Developed Countries ◽  
Hcv Infection ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Middle Income Countries ◽  
Low And Middle Income

Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. Only 1%–30% of patients in need of treatment may get it. In recent years, the availability of direct-acting antiviral agents (DAA) has been an important advancement in treating HCV infection. However, due to cost, it is not possible to receive these drugs in many countries where infection is endemic. In these low- and middle-income countries, the main barriers to controlling HCV infection are lack of knowledge about the infection, constraints on diagnostic testing and treatment, and lack of experts. Both national and international support are essential to overcoming these barriers. In low- and middle-income countries, interferon and ribavirin-based therapies still are the first choices due to their availability and to government payment support. In addition, in developed countries, efforts to provide lower-cost DAA drugs continue. Pharmaceutical companies continue to research manufacture of bio-equivalent drugs to reduce treatment costs. Considering the fake drug market, all developments need to be monitored closely by the institutions involved. This review focuses on barriers to hepatitis C treatment and ways to overcome those barriers.

scholarly journals Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study (Preprint)

2019 ◽  
Author(s):  
Bridget Louise Draper ◽  
Alisa Pedrana ◽  
Jessica Howell ◽  
Win Lei Yee ◽  
Hla Htay ◽  
...  
Keyword(s):  
Hepatitis C ◽  
General Population ◽  
Feasibility Study ◽  
People Who Inject Drugs ◽  
Point Of Care ◽  
Community Based ◽  
Middle Income ◽  
Hepatitis C Rna ◽  
Direct Acting ◽  
Low And Middle Income

BACKGROUND The advent of direct-acting antivirals (DAAs) and point-of-care (POC) testing platforms for hepatitis C allow for the decentralization of care to primary care settings. In many countries, access to DAAs is generally limited to tertiary hospitals, with limited published research documenting decentralized models of care in low-and middle-income settings. OBJECTIVE This study aims to assess the feasibility, acceptability, effectiveness, and cost-effectiveness of decentralized community-based POC testing and DAA therapy for hepatitis C among people who inject drugs and the general population in Yangon, Myanmar. METHODS Rapid diagnostic tests for anti-hepatitis C antibodies were carried out on-site and, if reactive, were followed by POC GeneXpert hepatitis C RNA polymerase chain reaction tests. External laboratory blood tests to exclude other major health issues were undertaken. Results were given to participants at their next appointment, with the participants commencing DAA therapy that day if a specialist review was not required. Standard clinical data were collected, and the participants completed behavioral questionnaires. The primary outcome measures are the proportion of participants receiving GeneXpert hepatitis C RNA test, the proportion of participants commencing DAA therapy, the proportion of participants completing DAA therapy, and the proportion of participants achieving sustained virological response 12 weeks after completing DAA therapy. RESULTS Recruitment was completed on September 30, 2019. Monitoring visits and treatment outcome visits are scheduled to continue until June 2020. CONCLUSIONS This feasibility study in Myanmar contributes to the evidence gap for community-based hepatitis C care in low- and middle-income settings. Evidence from this study will inform the scale-up of hepatitis C treatment programs in Myanmar and globally. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/16863

Sign in / Sign up

Export Citation Format

Share Document